Login to Your Account



Antisoma Cancer Drug Shows Good Phase II Prostate Data

By Nuala Moran


Wednesday, August 20, 2008
LONDON - Antisoma plc reported further clinical progress with its first-in-class vascular disrupting agent ASA404, announcing two-year survival of 33 percent in hormone refractory prostate cancer patients receiving ASA404 plus docetaxel, vs. 23 percent in the control group, which received docetaxel alone. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription